ClinicalTrials.gg
CompletedNCT04577352MOVE-FAUpdated Apr 13, 2026Results posted

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

A Phase 2/3 interventional study of Vatiquinone and Placebo in Friedreich Ataxia, sponsored by PTC Therapeutics. Completed at 14 sites in 9 countries. Open to participants aged 7 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by PTC Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
7 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
4th of 49
146 · median 32
Started
2020
with 2 others
Phase 2/3
2 of 71
none open now
Registered
40th of 71
by date
Lead sponsor
6 of 71
PTC Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 4th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 in phase 2/3, and was the 40th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 7 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale [mFARS]) and safety of vatiquinone in participants with Friedreich ataxia (FA).

Read the detailed description

During the double-blind, placebo-controlled phase, participants will be stratified by baseline mFARS score (\<40 versus ≥40), age of disease onset (\<14 versus ≥14), and age at screening (≤21 years or >21 years) and randomized to receive either vatiquinone or placebo using interactive response technology (IRT). Following completion of the randomized, double-blind, placebo-controlled phase (72 weeks), participants will enter into an open-label extension phase (24 weeks) during which they will receive open-label treatment with vatiquinone at the dose they received in the randomized phase of the study (for participants entering the extension phase who initially received placebo, the dose of vatiquinone will be determined based on age and weight) and then a safety follow-up (approximately 30 days [±5 days] after last dose or termination visit, whichever is later).

The primary efficacy analysis will be based on change from baseline in mFARS score of participants between 7 and 21 years old. In order to explore the treatment efficacy and safety, approximately an additional 20 participants >21 years of age will be randomized for a total of approximately 126 participants.

03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
7 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mFARS ≥20 to ≤70 at baseline
  • Must be able to ambulate at least 10 feet in 1 minute with or without assistance (non-wheelchair).
  • Friedreich ataxia diagnosis (homozygous for guanine-adenine-adenine [GAA] repeat expansion in intron-1 of frataxin [FXN] gene), confirmed by clinical testing (Note: size of GAA repeat is not required for eligibility)
  • Consent to comply with study procedures. For participants under the age of 18 (or age of consent), parent(s)/legal guardian(s) of the participant must agree to comply with the requirements of the study, including the need for frequent and prolonged follow up; parent(s)/legal guardian(s) with custody of the participant must give their consent for participant to enroll in the study.
  • Difference in the mFARS at screening and baseline of no more than 4 points.
  • Must be able to abstain from anticoagulants and any aspirin (including 81 mg) for 30 days prior to the baseline visit and for the duration of the study; any possible discontinuation of anticoagulants should be monitored and indicated by a specialist (for example, cardiologist, neurologist, or hematologist) and discontinuation will be noted by the prescribing physician.
  • Must be able to abstain from potent cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice or any grapefruit product) for at least 30 days prior to enrollment
  • Must be able to swallow capsules
  • Males and females of must be willing to use an effective method of from the time consent is signed until 30 days after the last dose of study drug or early termination visit. Male participants must agree not to donate sperm during the study and for at least 30 days after the last dose of study drug or early termination visit.

Exclusion criteria

Exclusion Criteria:

  • Individuals with clinical diagnosis of FA who have point mutations or deletions or other non-GAA expansion mutations
  • Previous treatment with vatiquinone
  • Allergy to vatiquinone, sesame oil, gelatin (bovine and/or porcine), titanium dioxide, or red iron oxide
  • \<50%
  • Uncontrolled diabetes ( [HbA1c] >7.0%) at the time of screening
  • Has current suicidal ideation based on Columbia-Suicide Severity Rating Scale (C-SSRS) within 3 months prior to screening or between screening and baseline at the baseline visit or suicidal behavior within the last year at the screening visit or between screening and baseline at the baseline visit
  • Pregnant or lactating participants or those sexually active participants who are unwilling to comply with proper methods; females of must have a negative pregnancy test at screening and during the baseline visit
  • (AST) or alanine aminotransferase (ALT) ≥2 * (ULN) at time of screening
  • (INR) ≥1.5 * ULN at time of screening or (CS) bleeding, as determined by the investigator
  • Serum creatinine ≥1.5 * ULN at time of screening
  • Comorbidities that may confound study results (for example, fat malabsorption syndrome, other mitochondrial disorder) in the opinion of the investigator
  • Participation in any other interventional clinical trial or received any drug in any other clinical trial within 60 days prior to the baseline visit. Participants may be rescreened after the exclusionary period of 60 days has passed.
  • Concomitant use of interventional coenzyme Q10 (CoQ10), vitamin E, or any approved or non-approved medication for FA within 30 days prior to the screening visit. These prohibited medications can be discontinued at the screening visit; if this is the case, the mFARS assessment must be repeated to confirm inclusion eligibility after a minimum of 30 days post-discontinuation and there must be no more than a 4-point difference in mFARS assessed from the post-discontinuation visit to the baseline visit.
  • Illicit drug use 30 days prior to screening and during the study is prohibited.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Vatiquinone

    Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.

    Drug: Vatiquinone

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.

    Drug: Vatiquinone · Drug: Placebo

Interventions

  • Vatiquinone will be administered per dose and schedule specified in the arm.

  • DrugPlacebo

    Placebo will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set

    mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. Total mFARS scores for each subscale: bulbar (0 to 5), upper limb coordination (0 to 36), lower limb coordination (0 to 16), and upright stability (0 to 36). mFARS total score was a composite score of all 4 subscales, ranging from 0 (normal) to 93 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated measures (MMRM).

    Time frame: Baseline, Week 72

  2. Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set

    mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. Total mFARS scores for each subscale: bulbar (0 to 5), upper limb coordination (0 to 36), lower limb coordination (0 to 16), and upright stability (0 to 36). mFARS total score was a composite score of all 4 subscales, ranging from 0 (normal) to 93 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Change From Baseline in Friedreich Ataxia Rating Scale Activities of Daily Living (FARS-ADL) Score at Week 72 - mITT Analysis Set

    The ADL component of the FARS includes 9 subscales: speech, swallowing, cutting food and handling utensils, dressing, personal hygiene, falling, walking, quality of sitting position, and bladder function. Each of these subscales is rated on a 5-point scale where 0=normal to 4=severe disability/inability to carry out activity independently for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  2. Change From Baseline in FARS-ADL Score at Week 72 - ITT Analysis Set

    The ADL component of the FARS includes 9 subscales: speech, swallowing, cutting food and handling utensils, dressing, personal hygiene, falling, walking, quality of sitting position, and bladder function. Each of these subscales is rated on a 5-point scale where 0=normal to 4=severe disability/inability to carry out activity independently for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  3. Change From Baseline in 1-Minute Walk Test (1MWT) at Week 72 - mITT Analysis Set

    The 1MWT is a timed performance test used to measure functional ability, walking endurance, balance, and muscle performance by measuring maximal walking speed in 1 minute. Participants were instructed to walk as quickly as possible for 1 minute without running. Maximal walking speed was measured upon completion of the walk and distance was recorded. The mean change from baseline in the distance the participant walked is reported. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  4. Change From Baseline in 1MWT at Week 72 - ITT Analysis Set

    The 1MWT is a timed performance test used to measure functional ability, walking endurance, balance, and muscle performance by measuring maximal walking speed in 1 minute. Participants were instructed to walk as quickly as possible for 1 minute without running. Maximal walking speed was measured upon completion of the walk and distance was recorded. The mean change from baseline in the distance the participant walked is reported. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  5. Number of Falls Per 28 Days Over Every 24-Week Period - mITT Analysis Set

    Each participant was required to maintain a fall log, which included the date and time of each fall. Falls as defined by World Health Organization as "inadvertently coming to rest on the ground, floor or other lower level, excluding intentional change in position to rest in furniture, wall or other objects," were reported. Number of falls per 28 days during a time interval was calculated as the number of falls during the period divided by the number of days during the interval, and multiplied by 28. The falls that occurred on or after the first Loss of Ambulation visit were excluded from the analysis.

    Time frame: Week 1-24, Week 25-48, and Week 49-72

  6. Number of Falls Per 28 Days Over Every 24-Week Period - ITT Analysis Set

    Each participant was required to maintain a fall log, which included the date and time of each fall. Falls as defined by World Health Organization as "inadvertently coming to rest on the ground, floor or other lower level, excluding intentional change in position to rest in furniture, wall or other objects," were reported. Number of falls per 28 days during a time interval was calculated as the number of falls during the period divided by the number of days during the interval, and multiplied by 28. The falls that occurred on or after the first Loss of Ambulation visit were excluded from the analysis.

    Time frame: Week 1-24, Week 25-48, and Week 49-72

Other outcomes

  1. Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - mITT Analysis Set

    mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The Upright Stability subscale of the mFARS includes following items: 1. Sitting posture (score: 0 to 4); 2a. Stance with feet apart and eyes open (score: 0 to 4); 2b. Stance with feet apart and eyes closed (score: 0 to 4); 3a. Stance with feet together and eyes open (score: 0 to 4); 3b. Stance with feet together and eyes closed (score: 0 to 4); 4. Tandem stance (score: 0 to 4); 5. Stance on dominant foot (score: 0 to 4); 6. Tandem walk (score: 0 to 3); 7. Gait (score: 0 to 5). The upright stability subscale total score ranges from 0 (normal) to 36 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  2. Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - ITT Analysis Set

    mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The Upright Stability subscale of the mFARS includes following items: 1. Sitting posture (score: 0 to 4); 2a. Stance with feet apart and eyes open (score: 0 to 4); 2b. Stance with feet apart and eyes closed (score: 0 to 4); 3a. Stance with feet together and eyes open (score: 0 to 4); 3b. Stance with feet together and eyes closed (score: 0 to 4); 4. Tandem stance (score: 0 to 4); 5. Stance on dominant foot (score: 0 to 4); 6. Tandem walk (score: 0 to 3); 7. Gait (score: 0 to 5). The upright stability subscale total score ranges from 0 (normal) to 36 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

    Time frame: Baseline, Week 72

  3. Change From Baseline in the Modified Fatigue Impact Scale (MFIS) Score at Week 72 - mITT Analysis Set

    The MFIS is a 21-item, reliable, validated instrument that has been utilized in many neurological disorders. It is a modified form of the Fatigue Impact Scale, a component of the Multiple Sclerosis Quality of Life Inventory. Each item was scored on a scale of 0 (never) to 4 (almost always). The total score was the sum of all item's score and ranged from 0 (no fatigue impact) to 84 (almost always impacted by fatigue). Higher scores indicated greater impact of fatigue on participant function.

    Time frame: Baseline, Week 72

  4. Change From Baseline in the MFIS Score at Week 72 - ITT Analysis Set

    The MFIS is a 21-item, reliable, validated instrument that has been utilized in many neurological disorders. It is a modified form of the Fatigue Impact Scale, a component of the Multiple Sclerosis Quality of Life Inventory. Each item was scored on a scale of 0 (never) to 4 (almost always). The total score was the sum of all item's score and ranged from 0 (no fatigue impact) to 84 (almost always impacted by fatigue). Higher scores indicated greater impact of fatigue on participant function.

    Time frame: Baseline, Week 72

07

Results

Posted Apr 8, 2026

Participant flow

Double-blind Phase (72 Weeks)
Participant flow — Double-blind Phase (72 Weeks)
MilestoneVatiquinonePlacebo
Started7373
Received at least 1 dose of study drug7373
Completed6365
Not completed108
Withdrew: Adverse event63
Withdrew: Withdrawal by subject32
Withdrew: Death01
Withdrew: Protocol violation01
Withdrew: Other than specified11
Open-label Phase (24 Weeks)
Participant flow — Open-label Phase (24 Weeks)
MilestoneVatiquinonePlacebo
Started6365
Received at least 1 dose of study drug6365
Completed6362
Not completed03
Withdrew: Adverse event02
Withdrew: Other than specified01

Outcome measures

PrimaryChange From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set

mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. Total mFARS scores for each subscale: bulbar (0 to 5), upper limb coordination (0 to 36), lower limb coordination (0 to 16), and upright stability (0 to 36). mFARS total score was a composite score of all 4 subscales, ranging from 0 (normal) to 93 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated measures (MMRM).

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the mFARS Score at Week 72 - Modified Intent-to-treat (mITT) Analysis Set1.218 ± 0.96522.828 ± 0.9994
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.1440 · Ls mean difference: -1.610 · 95% CI -3.769 to 0.550
PrimaryChange From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set

mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. Total mFARS scores for each subscale: bulbar (0 to 5), upper limb coordination (0 to 36), lower limb coordination (0 to 16), and upright stability (0 to 36). mFARS total score was a composite score of all 4 subscales, ranging from 0 (normal) to 93 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the mFARS Score at Week 72 - Intent-to-treat (ITT) Analysis Set0.898 ± 0.85002.555 ± 0.8770
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0984 · Ls mean difference: -1.657 · 95% CI -3.622 to 0.308
SecondaryChange From Baseline in Friedreich Ataxia Rating Scale Activities of Daily Living (FARS-ADL) Score at Week 72 - mITT Analysis Set

The ADL component of the FARS includes 9 subscales: speech, swallowing, cutting food and handling utensils, dressing, personal hygiene, falling, walking, quality of sitting position, and bladder function. Each of these subscales is rated on a 5-point scale where 0=normal to 4=severe disability/inability to carry out activity independently for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in Friedreich Ataxia Rating Scale Activities of Daily Living (FARS-ADL) Score at Week 72 - mITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in Friedreich Ataxia Rating Scale Activities of Daily Living (FARS-ADL) Score at Week 72 - mITT Analysis Set0.759 ± 0.59921.677 ± 0.6202
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.1382 · Ls mean difference: -0.918 · 95% CI -2.132 to 0.296
SecondaryChange From Baseline in FARS-ADL Score at Week 72 - ITT Analysis Set

The ADL component of the FARS includes 9 subscales: speech, swallowing, cutting food and handling utensils, dressing, personal hygiene, falling, walking, quality of sitting position, and bladder function. Each of these subscales is rated on a 5-point scale where 0=normal to 4=severe disability/inability to carry out activity independently for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in FARS-ADL Score at Week 72 - ITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in FARS-ADL Score at Week 72 - ITT Analysis Set0.707 ± 0.52191.692 ± 0.5402
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0820 · Ls mean difference: -0.985 · 95% CI -2.095 to 0.125
SecondaryChange From Baseline in 1-Minute Walk Test (1MWT) at Week 72 - mITT Analysis Set

The 1MWT is a timed performance test used to measure functional ability, walking endurance, balance, and muscle performance by measuring maximal walking speed in 1 minute. Participants were instructed to walk as quickly as possible for 1 minute without running. Maximal walking speed was measured upon completion of the walk and distance was recorded. The mean change from baseline in the distance the participant walked is reported. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · meters
Change From Baseline in 1-Minute Walk Test (1MWT) at Week 72 - mITT Analysis Set
metersVatiquinonePlacebo
Change From Baseline in 1-Minute Walk Test (1MWT) at Week 72 - mITT Analysis Set-4.324 ± 2.5882-9.290 ± 2.6843
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0800 · Ls mean difference: 4.966 · 95% CI -0.593 to 10.525
SecondaryChange From Baseline in 1MWT at Week 72 - ITT Analysis Set

The 1MWT is a timed performance test used to measure functional ability, walking endurance, balance, and muscle performance by measuring maximal walking speed in 1 minute. Participants were instructed to walk as quickly as possible for 1 minute without running. Maximal walking speed was measured upon completion of the walk and distance was recorded. The mean change from baseline in the distance the participant walked is reported. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · meters
Change From Baseline in 1MWT at Week 72 - ITT Analysis Set
metersVatiquinonePlacebo
Change From Baseline in 1MWT at Week 72 - ITT Analysis Set-4.623 ± 2.2113-9.462 ± 2.2687
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0551 · Ls mean difference: 4.839 · 95% CI -0.106 to 9.784
SecondaryNumber of Falls Per 28 Days Over Every 24-Week Period - mITT Analysis Set

Each participant was required to maintain a fall log, which included the date and time of each fall. Falls as defined by World Health Organization as "inadvertently coming to rest on the ground, floor or other lower level, excluding intentional change in position to rest in furniture, wall or other objects," were reported. Number of falls per 28 days during a time interval was calculated as the number of falls during the period divided by the number of days during the interval, and multiplied by 28. The falls that occurred on or after the first Loss of Ambulation visit were excluded from the analysis.

Time frame:
Week 1-24, Week 25-48, and Week 49-72
Reported as:
Mean · falls
Number of Falls Per 28 Days Over Every 24-Week Period - mITT Analysis Set
fallsVatiquinonePlacebo
Week 1-245.029 ± 14.46863.999 ± 6.9569
Week 25-484.098 ± 11.52893.900 ± 9.0212
Week 49-723.732 ± 10.07904.462 ± 12.1785
SecondaryNumber of Falls Per 28 Days Over Every 24-Week Period - ITT Analysis Set

Each participant was required to maintain a fall log, which included the date and time of each fall. Falls as defined by World Health Organization as "inadvertently coming to rest on the ground, floor or other lower level, excluding intentional change in position to rest in furniture, wall or other objects," were reported. Number of falls per 28 days during a time interval was calculated as the number of falls during the period divided by the number of days during the interval, and multiplied by 28. The falls that occurred on or after the first Loss of Ambulation visit were excluded from the analysis.

Time frame:
Week 1-24, Week 25-48, and Week 49-72
Reported as:
Mean · falls
Number of Falls Per 28 Days Over Every 24-Week Period - ITT Analysis Set
fallsVatiquinonePlacebo
Week 1-244.464 ± 13.56183.535 ± 6.5231
Week 25-483.920 ± 10.98503.518 ± 8.4701
Week 49-723.407 ± 9.60433.974 ± 11.4690
Other pre-specifiedChange From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - mITT Analysis Set

mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The Upright Stability subscale of the mFARS includes following items: 1. Sitting posture (score: 0 to 4); 2a. Stance with feet apart and eyes open (score: 0 to 4); 2b. Stance with feet apart and eyes closed (score: 0 to 4); 3a. Stance with feet together and eyes open (score: 0 to 4); 3b. Stance with feet together and eyes closed (score: 0 to 4); 4. Tandem stance (score: 0 to 4); 5. Stance on dominant foot (score: 0 to 4); 6. Tandem walk (score: 0 to 3); 7. Gait (score: 0 to 5). The upright stability subscale total score ranges from 0 (normal) to 36 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - mITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - mITT Analysis Set1.734 ± 0.49112.991 ± 0.5094
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0212 · Ls mean difference: -1.257 · 95% CI -2.325 to -0.188
Other pre-specifiedChange From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - ITT Analysis Set

mFARS is a 93-item scale; comprised of neurologic component of FARS. For each item, responses categorize the corresponding neurological finding, with a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The Upright Stability subscale of the mFARS includes following items: 1. Sitting posture (score: 0 to 4); 2a. Stance with feet apart and eyes open (score: 0 to 4); 2b. Stance with feet apart and eyes closed (score: 0 to 4); 3a. Stance with feet together and eyes open (score: 0 to 4); 3b. Stance with feet together and eyes closed (score: 0 to 4); 4. Tandem stance (score: 0 to 4); 5. Stance on dominant foot (score: 0 to 4); 6. Tandem walk (score: 0 to 3); 7. Gait (score: 0 to 5). The upright stability subscale total score ranges from 0 (normal) to 36 (greater impairment). A lower score = better neurological function. Missing data was imputed using pattern mix model multiple imputation. LS mean and SE was calculated using MMRM.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - ITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the Upright Stability Subscale of the mFARS at Week 72 - ITT Analysis Set1.379 ± 0.43212.489 ± 0.4468
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0246 · Ls mean difference: -1.110 · 95% CI -2.079 to -0.142
Other pre-specifiedChange From Baseline in the Modified Fatigue Impact Scale (MFIS) Score at Week 72 - mITT Analysis Set

The MFIS is a 21-item, reliable, validated instrument that has been utilized in many neurological disorders. It is a modified form of the Fatigue Impact Scale, a component of the Multiple Sclerosis Quality of Life Inventory. Each item was scored on a scale of 0 (never) to 4 (almost always). The total score was the sum of all item's score and ranged from 0 (no fatigue impact) to 84 (almost always impacted by fatigue). Higher scores indicated greater impact of fatigue on participant function.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Modified Fatigue Impact Scale (MFIS) Score at Week 72 - mITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the Modified Fatigue Impact Scale (MFIS) Score at Week 72 - mITT Analysis Set-0.756 ± 2.21974.291 ± 2.3344
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0252 · Ls mean difference: -5.048 · 95% CI -9.468 to -0.628
Other pre-specifiedChange From Baseline in the MFIS Score at Week 72 - ITT Analysis Set

The MFIS is a 21-item, reliable, validated instrument that has been utilized in many neurological disorders. It is a modified form of the Fatigue Impact Scale, a component of the Multiple Sclerosis Quality of Life Inventory. Each item was scored on a scale of 0 (never) to 4 (almost always). The total score was the sum of all item's score and ranged from 0 (no fatigue impact) to 84 (almost always impacted by fatigue). Higher scores indicated greater impact of fatigue on participant function.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · units on a scale
Change From Baseline in the MFIS Score at Week 72 - ITT Analysis Set
units on a scaleVatiquinonePlacebo
Change From Baseline in the MFIS Score at Week 72 - ITT Analysis Set-1.200 ± 1.98974.354 ± 2.0758
Statistical analysis
  • Vatiquinone vs Placebo · Mixed Models Analysis · p = = 0.0095 · Ls mean difference: -5.554 · 95% CI -9.750 to -1.358

Adverse events

Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Phase: Vatiquinone1/73 (1.4%)8/73 (11%)71/73 (97.3%)
Double-blind Phase: Placebo1/73 (1.4%)8/73 (11%)73/73 (100%)
On-Vatiquinone Period: Vatiquinone/Vatiquinone1/73 (1.4%)10/73 (13.7%)71/73 (97.3%)
On-Vatiquinone Period: Placebo/Vatiquinone0/65 (0%)2/65 (3.1%)53/65 (81.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventDouble-blind Phase: VatiquinoneDouble-blind Phase: PlaceboOn-Vatiquinone Period: Vatiquinone/VatiquinoneOn-Vatiquinone Period: Placebo/Vatiquinone
Suicide attemptPsychiatric disorders1/730/732/730/65
Impaired gastric emptyingGastrointestinal disorders0/730/730/731/65
NauseaGastrointestinal disorders0/730/730/731/65
VomitingGastrointestinal disorders0/730/730/731/65
COVID-19Infections and infestations0/730/730/731/65
PresyncopeNervous system disorders0/730/730/731/65
MyocarditisCardiac disorders1/731/731/730/65
Atrial fibrillationCardiac disorders0/731/730/730/65
Cardiac failureCardiac disorders1/730/731/730/65
Non-cardiac chest painGeneral disorders0/731/730/730/65
Most frequent other events
Showing 10 of 45
Most frequent other events
EventDouble-blind Phase: VatiquinoneDouble-blind Phase: PlaceboOn-Vatiquinone Period: Vatiquinone/VatiquinoneOn-Vatiquinone Period: Placebo/Vatiquinone
FallInjury, poisoning and procedural complications58/7361/7359/7334/65
COVID-19Infections and infestations32/7324/7336/734/65
HeadacheNervous system disorders22/7326/7325/737/65
DiarrhoeaGastrointestinal disorders19/7310/7321/735/65
VomitingGastrointestinal disorders14/739/7317/737/65
NasopharyngitisInfections and infestations12/7317/7312/736/65
NauseaGastrointestinal disorders13/7310/7315/735/65
FatigueGeneral disorders9/7313/7311/733/65
Upper respiratory tract infectionInfections and infestations9/738/7312/738/65
DizzinessNervous system disorders11/738/7312/737/65

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)VatiquinonePlaceboTotal
Mean18.9 ± 12.2418.2 ± 11.2718.6 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)VatiquinonePlaceboTotal
Female454287
Male283159
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VatiquinonePlaceboTotal
Hispanic or Latino10919
Not Hispanic or Latino6363126
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VatiquinonePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6869137
More than one race000
Unknown or Not Reported549
Modified Friedreich's Ataxia Rating Scale (mFARS) Score
Modified Friedreich's Ataxia Rating Scale (mFARS) Score(units on a scale)VatiquinonePlaceboTotal
Mean43.30 ± 10.75442.47 ± 11.63742.89 ± 11.163
08

Study locations

14 sites
  • UCLA
    Los Angeles, California 90095, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
  • University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology
    São Paulo, 13083-887, Brazil
  • Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)
    Montreal, Quebec H2X 0A9, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T1C5, Canada
  • Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)
    Paris, 75646, France
  • Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)
    Tübingen, 72076, Germany
  • Ospedale Pediatrico Bambino Gesu' IRCCS
    Roma, 00165, Italy
  • CBR Neurogenetic Research Clinic, University of Auckland
    Auckland, 1023, New Zealand
  • Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares
    Barcelona, 08950, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Apr 2023, 27 months.

Results were first posted in Apr 2026, 3 years after primary completion. A results delay was requested in Mar 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 6, 2020
StartActual
Dec 17, 2020
Primary completionActual
Apr 4, 2023
CompletionActual
Oct 2, 2023
Results delay requested
Mar 25, 2024
Results first posted
Apr 8, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04577352
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Dec 17, 2020
Primary completion
Apr 4, 2023
Completion
Oct 2, 2023
Results posted
Apr 8, 2026
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion